StockMacro
Menu

Bausch + Lomb

$19.38 +23% in 6 monthsMarket cap $6.9B

BLCO on XNYS, Health Care, Bausch + Lomb Corporation, job postings

Measures activity, not value. Not investment advice.

Shares rose 33% over 12 months but the company lost $111M on $5.4B of revenue.

  • WatchDebt of $5B against $513M of cash on the balance sheet

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.

Industry
Ophthalmic goods (Health Care)
Employees
13,000
Website
bausch.com
Listed
NYSE, US
Last results
28 Oct 2026
Next results
expected around 17 Feb 2027 (an estimate: a year ago it reported on 18 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.4B, net income $32.0M.
Quarter to 31 Dec 2021: revenue $1.0B, net income $51.0MQuarter to 31 Dec 2021: revenue $1.0B, net income $51.0MQuarter to 31 Mar 2022: revenue $889.0M, net income $20.0MQuarter to 31 Mar 2022: revenue $889.0M, net income $20.0MQuarter to 30 Jun 2022: revenue $941.0M, net income $5.0MQuarter to 30 Jun 2022: revenue $941.0M, net income $5.0MQuarter to 30 Sep 2022: revenue $942.0M, net income -$18.0MQuarter to 30 Sep 2022: revenue $942.0M, net income -$18.0MQuarter to 31 Dec 2022: revenue $996.0M, net income -$1.0MQuarter to 31 Dec 2022: revenue $996.0M, net income -$1.0MQuarter to 31 Mar 2023: revenue $931.0M, net income -$90.0MQuarter to 31 Mar 2023: revenue $931.0M, net income -$90.0MQuarter to 30 Jun 2023: revenue $1.0B, net income -$32.0MQuarter to 30 Jun 2023: revenue $1.0B, net income -$32.0MQuarter to 30 Sep 2023: revenue $1.0B, net income -$84.0MQuarter to 30 Sep 2023: revenue $1.0B, net income -$84.0MQuarter to 31 Dec 2023: revenue $1.2B, net income -$54.0MQuarter to 31 Dec 2023: revenue $1.2B, net income -$54.0MQuarter to 31 Mar 2024: revenue $1.1B, net income -$167.0MQuarter to 31 Mar 2024: revenue $1.1B, net income -$167.0MQuarter to 30 Jun 2024: revenue $1.2B, net income -$151.0MQuarter to 30 Jun 2024: revenue $1.2B, net income -$151.0MQuarter to 30 Sep 2024: revenue $1.2B, net income $4.0MQuarter to 30 Sep 2024: revenue $1.2B, net income $4.0MQuarter to 31 Dec 2024: revenue $1.3B, net income -$3.0MQuarter to 31 Dec 2024: revenue $1.3B, net income -$3.0MQuarter to 31 Mar 2025: revenue $1.1B, net income -$212.0MQuarter to 31 Mar 2025: revenue $1.1B, net income -$212.0MQuarter to 30 Jun 2025: revenue $1.3B, net income -$62.0MQuarter to 30 Jun 2025: revenue $1.3B, net income -$62.0MQuarter to 30 Sep 2025: revenue $1.3B, net income -$28.0MQuarter to 30 Sep 2025: revenue $1.3B, net income -$28.0MQuarter to 31 Dec 2025: revenue $1.4B, net income -$58.0MQuarter to 31 Dec 2025: revenue $1.4B, net income -$58.0MQuarter to 31 Mar 2026: revenue $1.2B, net income -$71.0MQuarter to 31 Mar 2026: revenue $1.2B, net income -$71.0MQuarter to 30 Jun 2026: revenue $1.4B, net income -$14.0MQuarter to 30 Jun 2026: revenue $1.4B, net income -$14.0MQuarter to 30 Sep 2026: revenue $1.4B, net income $32.0MQuarter to 30 Sep 2026: revenue $1.4B, net income $32.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.4B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.4B$32.0M
30 Jun 2026$1.4B-$14.0M
31 Mar 2026$1.2B-$71.0M
31 Dec 2025$1.4B-$58.0M
30 Sep 2025$1.3B-$28.0M
30 Jun 2025$1.3B-$62.0M
31 Mar 2025$1.1B-$212.0M
31 Dec 2024$1.3B-$3.0M
30 Sep 2024$1.2B$4.0M
30 Jun 2024$1.2B-$151.0M
31 Mar 2024$1.1B-$167.0M
31 Dec 2023$1.2B-$54.0M
30 Sep 2023$1.0B-$84.0M
30 Jun 2023$1.0B-$32.0M
31 Mar 2023$931.0M-$90.0M
31 Dec 2022$996.0M-$1.0M
30 Sep 2022$942.0M-$18.0M
30 Jun 2022$941.0M$5.0M
31 Mar 2022$889.0M$20.0M
31 Dec 2021$1.0B$51.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $5.4B $5.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +8.9% +8.9%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$111.0M -$305.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.32 -$0.87
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 65.9%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 7.1% 1.8% 2.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -2.0% -6.1% 0.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -1.7% 0.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $252.0M -$196.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $513.0M $310.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $5.0B $5.0B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $4.5B $4.6B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.78 0.06
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $18.01
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 24.7
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.3 1.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.1 3.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.1 1.3

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Bausch + LombBLCO (this company) $6.9Bloss1.3+8.9%-2.0%
Cooper CompaniesCOO $11.2B19.62.6+4.7%13.5%
Warby ParkerWRBY $2.9B3853.1+9.9%0.8%
National VisionEYE $1.3B19.70.63+7.0%3.2%
Staar SurgicalSTAA $1.2Bover 9993.7+42%0.2%
PACSPACS $6.9B25.01.2+11%4.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$2.3M

bought $0, sold $2.3M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.1%

101 13F filers vs 98

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

9.2%

32.7M shares held by 13F filers (30 Sep 2026) of 357.5M outstanding (21 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.7%

2.6M shares sold short (30 Oct 2026) of 357.5M outstanding (21 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.3

2.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.9%

2.5M shares sold short in the report before, 2.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

56%

56% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+7.3%

$1.4B vs $1.3B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-26%

$55.0M vs $74.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$80K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $19.38 on 20 Nov 2026, +33% over 12 months (12-month range $14.56 to $21.37)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $2.3M in the last 12 months (the 12 months before: $268K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months, 0% on the 12 months before.
Revenue per quarter. Revenue $1.4B in the latest quarter, +7.3% on a year earlier.
Capital spending per quarter. Capital spending $55.0M in the latest quarter, -26% on a year earlier.
Institutional holders (13F filers). 101 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Lobbying spend. Lobbying spend: $80K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
28 Oct 20268-K and other filingsDirector or officer change
13 Oct 20268-K and other filingsDirector or officer change
6 Aug 20268-K and other filingsDirector or officer change
6 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jul 2026Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2026-06-30)
16 Jul 2026Lobbying filingnew lobbying registration (H.A. CUMBER & COMPANY, INC.)
16 Jul 2026Sharp changeFirst lobbying registration: first lobbying registration: BAUSCH & LOMB: new lobbying registration (H.A. CUMBER & COMPANY, INC.)
25 Feb 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 417K)
17 Dec 20258-K and other filingsDirector or officer change
17 Dec 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Aug 20258-K and other filingsA major agreement ended
18 Aug 20258-K and other filingsDirector or officer change
29 Jul 2025Sharp changeShort interest spike: short interest spike, 4.1M vs usual 1.9M (2025-07-15); 2.0x the same period a year earlier
23 Jul 20258-K and other filingsDirector or officer change
23 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 May 20248-K and other filingsDirector or officer change
29 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Feb 20248-K and other filingsDirector or officer change
28 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Feb 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 84.0M vs usual 39.5M (2023-12-31); 1.7x the same period a year earlier
29 Sep 20238-K and other filingsCompleted an acquisition or asset sale
1 Jun 20238-K and other filingsDirector or officer change
26 Apr 20238-K and other filingsDirector or officer change
12 Apr 20238-K and other filingsDirector or officer change
15 Feb 20238-K and other filingsDirector or officer change
22 Dec 20228-K and other filingsDirector or officer change
22 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Jul 20228-K and other filingsDirector or officer change
20 Jul 20228-K and other filingsDirector or officer change
23 Jun 20228-K and other filingsDirector or officer change
23 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Apr 20228-K and other filingsRegistered new securities for sale (S-1)
31 Mar 20228-K and other filingsRegistered new securities for sale (S-1)
13 Jan 20228-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 May 2022: -$597.1M published
Month from 1 Jun 2022: -$77.6M published
Month from 1 Aug 2024: $505K published
Month from 1 May 2025: $268K published
Month from 1 Feb 2026: $417K published
Month from 1 Mar 2026: $807K published
Month from 1 Aug 2026: -$1.2M published
Month from 1 Nov 2026: -$2.3M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jul 2026: 2 published
Revenue per quarter
Quarter ended 31 Mar 2021: $881.0M; public on 9 Jun 2022
Quarter ended 30 Jun 2021: $934.0M; public on 5 Aug 2022
Quarter ended 30 Sep 2021: $949.0M; public on 3 Nov 2022
Quarter ended 31 Dec 2021: $1.0B; public on 23 Feb 2023
Quarter ended 31 Mar 2022: $889.0M, +0.9% on a year earlier; public on 9 Jun 2022
Quarter ended 30 Jun 2022: $941.0M, +0.7% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $942.0M, -0.7% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $996.0M, -0.5% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $931.0M, +4.7% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $1.0B, +10% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $1.0B, +6.9% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $1.2B, +18% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $1.1B, +18% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $1.2B, +17% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $1.2B, +19% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $1.3B, +9.1% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $1.1B, +3.5% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $1.3B, +5.1% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $1.3B, +7.1% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $1.4B, +9.8% on a year earlier; public on 19 Feb 2026
Quarter ended 31 Mar 2026: $1.2B, +9.4% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $1.4B, +9.1% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $1.4B, +7.3% on a year earlier; public on 29 Oct 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $45.0M; public on 9 Jun 2022
Quarter ended 30 Jun 2021: $45.0M; public on 5 Aug 2022
Quarter ended 30 Sep 2021: $41.0M; public on 3 Nov 2022
Quarter ended 31 Dec 2021: $62.0M; public on 23 Feb 2023
Quarter ended 31 Mar 2022: $42.0M, -6.7% on a year earlier; public on 9 Jun 2022
Quarter ended 30 Jun 2022: $34.0M, -24% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $49.0M, +20% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $50.0M, -19% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $37.0M, -12% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $27.0M, -21% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $33.0M, -33% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $84.0M, +68% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $67.0M, +81% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $72.0M, +167% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $60.0M, +82% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $92.0M, +9.5% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $110.0M, +64% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $89.0M, +24% on a year earlier; public on 31 Jul 2025
Quarter ended 30 Sep 2025: $74.0M, +23% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $76.0M, -17% on a year earlier; public on 19 Feb 2026
Quarter ended 31 Mar 2026: $100.0M, -9.1% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $71.0M, -20% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $55.0M, -26% on a year earlier; public on 29 Oct 2026
Institutional holders (13F filers)
30 Jun 2022 report: 67; public on 15 Aug 2022
30 Sep 2022 report: 68; public on 14 Nov 2022
31 Dec 2022 report: 81; public on 14 Feb 2023
31 Mar 2023 report: 71; public on 15 May 2023
30 Jun 2023 report: 71; public on 14 Aug 2023
30 Sep 2023 report: 82; public on 14 Nov 2023
31 Dec 2023 report: 85; public on 14 Feb 2024
31 Mar 2024 report: 84; public on 15 May 2024
30 Jun 2024 report: 82; public on 14 Aug 2024
30 Sep 2024 report: 106; public on 14 Nov 2024
31 Dec 2024 report: 111; public on 14 Feb 2025
31 Mar 2025 report: 105; public on 15 May 2025
30 Jun 2025 report: 91; public on 14 Aug 2025
30 Sep 2025 report: 90; public on 14 Nov 2025
31 Dec 2025 report: 97; public on 17 Feb 2026
31 Mar 2026 report: 96; public on 15 May 2026
30 Jun 2026 report: 98; public on 14 Aug 2026
30 Sep 2026 report: 101; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $50K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $2.3M (2 Nov 2026), higher than 85% of its own history.
  • First lobbying registration: registered for federal lobbying for the first time in our data (H.A. Cumber & Company, Inc.) Public on 16 Jul 2026.
  • Lobbying on a new issue: lobbying on a new issue Public on 19 Jul 2026.
  • Insider net buying (open market): Insiders sold a net $2.3M in the last 12 months (the 12 months before: $268K).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 17 insider trades

Last 90 days: 1 sale, $2.3M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Nov 2026Frederick MunschSVP, Controller and CAOSellafter exercising options112,015$20.48$2.3MForm 4
12 Aug 2026Frederick MunschSVP, Controller and CAOSell52,900$16.78$888KForm 4
10 Aug 2026Andrew C. Von EschenbachDirectorSell18,559$16.53$307KForm 4
10 Mar 2026A Robert D BaileyEVP & Chief Legal OfficerBuy14,600$17.15$250KForm 4
10 Mar 2026Brent L SaundersCEO and Chairman of the BoardBuy14,700$17.14$252KForm 4
10 Mar 2026Sam EldessoukyEVP and CFOBuy4,000$17.13$69KForm 4
4 Mar 2026Thomas W. Ross Sr.DirectorBuy4,500$17.68$80KForm 4
3 Mar 2026Andrew C. Von EschenbachDirectorBuy4,364$18.31$80KForm 4

101 institutions reported shares at the end of Q3 2026, 9% of the shares outstanding; 13 opened a position, 10 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BROOKFIELD Corp4.6M1.28%$77.6MNew+4.6M
D. E. Shaw & Co., Inc.3.4M0.95%$57.5M+57K+1.7%
Deutsche Bank AG\3.3M0.93%$56.6M-94K-2.7%
Davidson Kempner Capital Management LP3.2M0.88%$53.7MNo change
Goldentree Asset Management LP3.1M0.87%$52.7M+446K+17%
Icahn Carl C2.4M0.67%$40.4M-1.1M-32%
T. Rowe Price Associates Inc2.2M0.62%+72K+3.3%
Glenview Capital Management, LLC1.9M0.53%$32.0M-38K-2.0%
Arrowstreet Capital, Limited Partnership1.5M0.43%$26.3M+182K+13%
Caspian Capital LP1.4M0.40%$24.2M-577K-29%

Company events

All 29 company events

In 12 months: 4 director or officer changes, 2 major agreements. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Oct 2026Director or officer change8-K
13 Oct 2026Director or officer change8-K
6 Aug 2026Director or officer change; Signed a major agreement8-K
2 Jan 2026Signed a major agreementSame filing: took on new debt8-K
17 Dec 2025Director or officer change8-K
18 Aug 2025Director or officer change; A major agreement ended8-K
23 Jul 2025Director or officer change8-K
27 Jun 2025Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $50K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
15 Jun 2026NewH.A. Cumber & Company, Inc.for Bausch & LombFood and Drug Administration approvalsMED, PharmacyFiling
15 Mar 2013EndedPolicy Directions Inc.for Bausch & LombNot statedFiling
14 Aug 2007NewHill & Knowlton Strategies, LLCfor Bausch & LombHealth issuesFiling
30 Jun 2007EndedHill & Knowlton Strategies, LLCfor Bausch & LombNot statedFiling

The 5 newest of 130 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 28 Oct 2026Filings record

    Director or officer change

  2. 13 Oct 2026Filings record

    Director or officer change

  3. 6 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 6 Aug 2026Filings record

    Director or officer change

  5. 19 Jul 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4554314
  6. 16 Jul 2026Lobbying change

    registered for federal lobbying for the first time in our data (H.A. Cumber & Company, Inc.).

    See the evidence (1 source record)
    Source coverage starts
    3 Jan 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  7. 16 Jul 2026Lobbying record

    BAUSCH & LOMB: new lobbying registration (H.A. CUMBER & COMPANY, INC.) (dated 15 Jun 2026)

  8. 11 Mar 2026Insiders record

    Bailey A Robert D (EVP & Chief Legal Officer) bought 14,600 shares of BLCO ($250,390) (dated 10 Mar 2026)

  9. 11 Mar 2026Insiders record

    SAUNDERS BRENT L (CEO and Chairman of the Board) bought 14,700 shares of BLCO ($251,958) (dated 10 Mar 2026)

  10. 11 Mar 2026Insiders record

    Eldessouky Sam (EVP and CFO) bought 4,000 shares of BLCO ($68,520) (dated 10 Mar 2026)

  11. 5 Mar 2026Insiders record

    Ross Thomas W. Sr. (director) bought 4,500 shares of BLCO ($79,560) (dated 4 Mar 2026)

  12. 4 Mar 2026Insiders record

    VON ESCHENBACH ANDREW C. (director) bought 4,364 shares of BLCO ($79,905) (dated 3 Mar 2026)

  13. 4 Mar 2026Insiders record

    Alfonso Eduardo (director) bought 4,300 shares of BLCO ($76,970) (dated 3 Mar 2026)

  14. 25 Feb 2026Insiders change

    had 3 insiders buy $417K of its shares on the open market within 30 days (3 filings).

    Who bought: Ling Karen, Robertson Russel C, Collis Steven H.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $417K
    Window
    26 Jan 2026 to 25 Feb 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  15. 25 Feb 2026Insiders record

    COLLIS STEVEN H (director) bought 15,000 shares of BLCO ($267,150) (dated 24 Feb 2026)

  16. 25 Feb 2026Insiders record

    ROBERTSON RUSSEL C (director) bought 4,400 shares of BLCO ($78,760) (dated 24 Feb 2026)

  17. 24 Feb 2026Insiders record

    Ling Karen (director) bought 4,000 shares of BLCO ($70,960) (dated 23 Feb 2026)

  18. 17 Dec 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 17 Dec 2025Filings record

    Director or officer change

  20. 18 Aug 2025Filings record

    Director or officer change

  21. 18 Aug 2025Filings record

    A major agreement ended

  22. 25 Jul 2025Short interest and volume change

    had 4.1M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

    Same report last year: 2.1M; its normal report is 1.9M.

    See the evidence
    This period
    4.1M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    386K
    How far from its usual level
    +3.9
    Same report last year
    2.1M
    History used
    1,159 days
    2024-07-15: 2.1M2024-07-31: 1.7M2024-08-15: 1.9M2024-08-30: 2.2M2024-09-13: 2.2M2024-09-30: 1.4M2024-10-15: 1.5M2024-10-31: 1.1M2024-11-15: 967K2024-11-29: 1.1M2024-12-13: 1.2M2024-12-31: 1.2M2025-01-15: 1.3M2025-01-31: 1.7M2025-02-14: 1.2M2025-02-28: 1.9M2025-03-14: 2.0M2025-03-31: 2.0M2025-04-15: 2.0M2025-04-30: 1.9M2025-05-15: 2.6M2025-05-30: 2.5M2025-06-13: 2.6M2025-06-30: 3.4M2025-07-15: 4.1M
    the 15 Jul 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 23 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 23 Jul 2025Filings record

    Director or officer change

  25. 28 May 2025Insiders record

    SAUNDERS BRENT L (CEO and Chairman of the Board) bought 22,000 shares of BLCO ($248,160) (dated 27 May 2025)

  26. 7 May 2025Insiders record

    VON ESCHENBACH ANDREW C. (director) bought 1,695 shares of BLCO ($19,933) (dated 6 May 2025)

  27. 8 Aug 2024Insiders record

    SAUNDERS BRENT L (CEO and Chairman of the Board) bought 32,250 shares of BLCO ($505,035) (dated 7 Aug 2024)

  28. 29 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 29 May 2024Filings record

    Director or officer change

  30. 28 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 28 Feb 2024Filings record

    Director or officer change

  32. 27 Feb 2024Financials change

    spent $84.0M on capital projects in the quarter ended 31 Dec 2023, 1.7× the same quarter last year.

    Same quarter last year: $50.0M; its normal quarter is $39.5M.

    See the evidence
    This period
    $84.0M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $39.5M
    Typical spread (median absolute deviation)
    $8.0M
    How far from its usual level
    +3.8
    Same quarter last year
    $50.0M
    History used
    1,005 days
    2021-12-31: $62.0M2022-03-31: $42.0M2022-06-30: $34.0M2022-09-30: $49.0M2022-12-31: $50.0M2023-03-31: $37.0M2023-06-30: $27.0M2023-09-30: $33.0M2023-12-31: $84.0M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $39.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  33. 29 Sep 2023Filings record

    Completed an acquisition or asset sale

  34. 1 Jun 2023Filings record

    Director or officer change

  35. 26 Apr 2023Filings record

    Director or officer change

  36. 12 Apr 2023Filings record

    Director or officer change

  37. 15 Feb 2023Filings record

    Director or officer change

  38. 22 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 22 Dec 2022Filings record

    Director or officer change

  40. 27 Jul 2022Filings record

    Director or officer change

Showing the newest 40 of 49 entries; narrow the window or the kind of data to see older ones.

Not listed: 63 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001860742
Ticker
BLCO
Domain
bausch.com
Employer name
Bausch & Lomb Americas Inc. (1 unverified)
Hq location
A6|VAUGHAN|L4K 4 (1 unverified)
Lobbying client
bausch and lomb
Name
AcuFocus Australia Pty. Ltd, AcuFocus Holdings, Inc, AcuFocus, Inc, Alden Optical Laboratories, Inc and 75 more
  • DOL H-1B labor condition applications and PERM certifications64 data points16 Aug 2021 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)4 records, 111 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings162 data points30 Jun 2022 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)79 records13 Jan 2022 to 28 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)350 data points31 Dec 2019 to 21 Oct 2026
  • SEC Form 4 insider transactions17 records, 52 data points12 May 2022 to 2 Nov 2026
  • FINRA short interest (twice monthly)323 data points13 May 2022 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2282 data points6 May 2022 to 20 Nov 2026